Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review
BackgroudHuman epithelial growth factor receptor 2 (HER2) amplification is an important mechanism of acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy in non-small cell lung cancer (NSCLC) patients. For patients with both EGFR mutation and HER2 amplification, there is curre...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2024-08-01
|
| Schriftenreihe: | Frontiers in Oncology |
| Schlagworte: | |
| Online-Zugang: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1397238/full |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|